Has Wesley Smith, DO received payments from drug or device companies?

Yes. Drug and device makers reported $5,342 in general payments to Wesley Smith, DO across 122 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Wesley Smith, DO did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Wesley Smith, DO come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Wesley Smith, DO

Hematology & Oncology · Huntsville, ALNPI 1316472525

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,243 of the $5,342 with a category attached, or 60.7%. 36 manufacturers reported payments, led by Pfizer at 31.4% of the total. 2025 is the largest year on record at $3,669, more than ten times the $130 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in AL, where the typical reported total is $7,159.

$5,342in general payments, 2019–2025

Across 122 payments — averaging $43.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$2K
AstraZeneca$354
Boehringer Ingelheim$247
Novartis$233
E.r. Squibb & Sons, L.L.C.$233
Lilly USA, LLC$214
plus $2K from 30 others

What the payments were for

Consulting fees$1,30024%
Speaking & faculty fees$1202%
Food & beverage$3,24361%
Education$67813%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	13	$1,677
AstraZeneca(2 entities)	13	$354
Boehringer Ingelheim	5	$247
Novartis	9	$233
E.r. Squibb & Sons, L.L.C.	8	$233
Lilly USA, LLC	2	$214
Daiichi Sankyo Inc.	8	$204
Beigene USA, Inc.	4	$203
Seagen Inc.	2	$200
Takeda Pharmaceuticals U.S.A., Inc.	2	$182
Gilead(2 entities)	2	$169
Incyte Corporation	3	$138
Medtronic	1	$131
GSK	2	$129
Johnson & Johnson	2	$116
Beone Medicines USA, Inc.	6	$90
Bristol Myers Squibb	4	$88
Merck	4	$84
Blueprint Medicines Corporation	3	$77
Eisai Inc.	3	$71
Agios Pharmaceuticals, Inc.	2	$50
Stemline Therapeutics Inc.	2	$49
Exelixis Inc.	2	$48
Array Biopharma Inc	3	$46
Servier Pharmaceuticals LLC	3	$43
Sanofi	2	$39
Bard Peripheral Vascular, Inc.	1	$37
AVEO Pharmaceuticals, Inc.	2	$34
Regeneron Healthcare Solutions, Inc.	2	$32
Sobi, Inc	1	$24
Jazz Pharmaceuticals Inc.	1	$22
Deciphera Pharmaceuticals Inc.	1	$18
Recordati_rare_diseases_inc.	1	$17
Iovance Biotherapeutics, Inc.	1	$17
Genmab U.S., Inc.	1	$16
Edwards Lifesciences	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

IBRANCE$1,418
Yescarta$149
BRUKINSA$144
INTERSTIM$131
TUKYSA$118
BLENREP$112
OJJAARA$112

How this compares

$5,342 in reported general payments places this provider in the 40th percentile of 177 hematology & oncology providers in Alabama.

See all hematology & oncology providers in Alabama →

Medicare billing

Part B allowed, 2024

$522,825

Medicare patients

226

Services billed

20,030

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Huntsville

Ehab ElbaheshHuntsville$47K
Ali HachemHuntsville$20K
Daniel SchreederHuntsville$16K
Jorge Diaz CastroHuntsville$14K
Amitkumar MehtaBirmingham$683K
Pankit VachhaniBirmingham$545K
Luciano CostaBirmingham$409K
Khaleel AshrafBirmingham$379K
Michael BirrerBirmingham$302K
Rudolph NavariBirmingham$254K

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →